Troy Wichterman Sells 894 Shares of BioLife Solutions, Inc. (NASDAQ:BLFS) Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 894 shares of the firm’s stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $23.15, for a total transaction of $20,696.10. Following the completion of the transaction, the chief financial officer now owns 123,494 shares in the company, valued at approximately $2,858,886.10. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Monday, September 16th, Troy Wichterman sold 611 shares of BioLife Solutions stock. The shares were sold at an average price of $25.12, for a total transaction of $15,348.32.
• On Wednesday, August 21st, Troy Wichterman sold 142 shares of BioLife Solutions stock. The shares were sold at an average price of $25.61, for a total transaction of $3,636.62.

BioLife Solutions Stock Performance

Shares of BLFS opened at $24.07 on Friday. The firm’s 50 day moving average is $24.04 and its 200-day moving average is $22.16. The stock has a market capitalization of $1.11 billion, a P/E ratio of -14.24 and a beta of 1.88. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 1.81. BioLife Solutions, Inc. has a 12-month low of $9.92 and a 12-month high of $26.73.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.08. The company had revenue of $28.33 million for the quarter, compared to analysts’ expectations of $23.80 million. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. Equities research analysts anticipate that BioLife Solutions, Inc. will post -0.36 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BLFS. Principal Financial Group Inc. boosted its holdings in shares of BioLife Solutions by 2.1% in the first quarter. Principal Financial Group Inc. now owns 191,231 shares of the medical equipment provider’s stock worth $3,547,000 after buying an additional 3,925 shares during the period. BNP Paribas Financial Markets boosted its holdings in shares of BioLife Solutions by 249.5% in the first quarter. BNP Paribas Financial Markets now owns 53,515 shares of the medical equipment provider’s stock worth $993,000 after buying an additional 38,201 shares during the period. Geneva Capital Management LLC boosted its holdings in shares of BioLife Solutions by 0.7% in the first quarter. Geneva Capital Management LLC now owns 880,215 shares of the medical equipment provider’s stock worth $16,328,000 after buying an additional 5,730 shares during the period. Texas Permanent School Fund Corp boosted its holdings in shares of BioLife Solutions by 4.7% in the first quarter. Texas Permanent School Fund Corp now owns 31,145 shares of the medical equipment provider’s stock worth $578,000 after buying an additional 1,384 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new position in shares of BioLife Solutions in the first quarter worth about $335,000. 93.24% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the stock. Craig Hallum lifted their price objective on shares of BioLife Solutions from $23.00 to $30.00 and gave the company a “buy” rating in a research report on Monday, August 12th. TD Cowen raised their target price on shares of BioLife Solutions from $20.00 to $26.00 and gave the company a “buy” rating in a research note on Wednesday, July 17th. Northland Securities raised their target price on shares of BioLife Solutions from $26.00 to $28.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, HC Wainwright began coverage on shares of BioLife Solutions in a research note on Monday, September 30th. They set a “buy” rating and a $29.00 target price on the stock. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. According to MarketBeat, BioLife Solutions presently has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.